Valid Ghana · FDA Ghana

NATRILIX SR​ ​TABLETS

Indapamide

FDA/SD.255-030411 Indapamide 1.5mg cardiovascular system INN generic

What it does

Indapamide is a medication that helps to lower blood pressure and reduce swelling by helping the body get rid of excess fluid.

Commonly used for: high blood pressure (hypertension), swelling (oedema)

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
FDA/SD.255-030411
Registration date
2025-03-05
Expiry date
2030-09-01
Status
Valid
Active ingredient
Indapamide
Dosage form
Indapamide
Strength
1.5mg
Pack size
-
Therapeutic class
-
ATC class (WHO)
C03BA - Sulfonamides, plain
RxNorm RxCUI
5764
Manufacturer / MAH
Les Laboratoires Servier
Country of origin
-
Manufacturer location
905 Rte de Saran, 45520 Gidy, France

Source: Food and Drugs Authority · fetched 2026-04-18 08:48:42 · updated 2026-09-25 04:00:10

Disclaimer: This information is sourced from Food and Drugs Authority (Ghana). Always consult a qualified healthcare professional before using any medication.

About this medicine

Indapamide is a medication that helps to lower blood pressure and reduce swelling by helping the body get rid of excess fluid.

What it treats

  • high blood pressure (hypertension)
  • swelling (oedema)

How it works

It works by increasing the amount of urine your body makes, which helps to lower blood pressure and reduce fluid retention.

Who it's for

It is prescribed for adults with high blood pressure or conditions that cause swelling.

Drug class

Thiazide diuretics

Cautions

  • • Be careful if you are taking other medications that lower blood pressure.
  • • Caution is needed with drugs that can lower potassium levels in the blood.
  • • Watch out for medications that can cause low sodium levels.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: Indapamide

BNF-referenced

Indapamide is a thiazide-like diuretic primarily used for the treatment of hypertension. It exerts its antihypertensive effects by inhibiting sodium and chloride reabsorption at the distal convoluted tubule of the nephron. This results in increased urine output and a reduction in blood pressure. Indapamide is also thought to have additional mechanisms that contribute to its blood pressure-lowering effects, beyond its diuretic action.

Indications

  • Essential hypertension
  • Management of fluid retention

Dosage

Adults: For adult patients, the usual dose is 2.5 mg once daily, which should be taken in the morning. In cases where a modified-release formulation is used, the dose may

Mechanism of action

Indapamide acts on the nephron, specifically at the proximal segment of the distal convoluted tubule where it inhibits the Na+/Cl- cotransporter. This inhibition leads to reduced sodium reabsorption, causing sodium and water to remain in the nephron lumen for urinary excretion. Consequently, this results in decreased plasma volume, venous return, and cardiac output, ultimately lowering blood pressure. Additionally, indapamide may decrease responsiveness to pressor agents and reduce peripheral resistance, although these mechanisms require further investigation.

Pharmacodynamics

Indapamide is classified as a sulfonamide diuretic and is recognized for its efficacy in managing hypertension and preventing target organ damage. It induces water and electrolyte loss, with higher doses correlating with increased diuresis. Indapamide can cause significant electrolyte disturbances, such as hypokalemia, which may lead to QTc prolongation. It also influences plasma levels of renin and aldosterone while decreasing calcium excretion. Importantly, studies indicate that indapamide does not significantly alter glucose tolerance in hypertensive patients, although long-term metabolic effects remain to be fully elucidated.

Pharmacokinetics

Indapamide is absorbed orally and has a bioavailability that can be affected by food. It is extensively metabolized in the liver, with metabolites primarily excreted in urine. The drug has a half-life of approximately 14 to 18 hours, allowing for once-daily dosing. Renal function can influence the pharmacokinetics of indapamide, necessitating caution in patients with renal impairment due to the risk of hyperkalaemia.

Contra-indications

  • Hypersensitivity to sulfonamides
  • Severe renal impairment

Adverse effects

  • Hypokalemia
  • Dehydration
  • Electrolyte disturbances
  • Hypotension
  • Dizziness
  • Dry mouth
  • Fatigue
  • Restlessness
  • Angina pectoris
  • Arrhythmias
  • Arthralgia
  • Asthenia
  • Chest pain
  • Confusion
  • Severe cutaneous adverse reactions
  • Vision disorders
  • Rhabdomyolysis
  • QT interval prolongation

Interactions

  • Potassium-sparing diuretics
  • Thiazide diuretics
  • Pressor agents
  • Other antihypertensives

Precautions

  • Caution in diabetes mellitus
  • Caution in elderly patients
  • Monitor electrolytes regularly
  • Caution in patients with a history of acute porphyrias
  • Caution in hepatic disorders

Pregnancy

No information available; use with caution and consult healthcare professional.

Breast-feeding

Avoid; no information regarding safety in breast milk.

Storage

Store at room temperature, away from moisture and heat.

Formulations

  • 2.5 mg immediate-release tablet
  • 1.5 mg modified-release tablet
BNF 85 (British National Formulary) p.203 PubChem / pathway

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Molecular reference: Indapamide

PubChem CID 3702

Molecular formula: C16H16ClN3O3S

Mechanism of action

Indapamide acts on the nephron, specifically at the proximal segment of the distal convoluted tubule where it inhibits the Na+/Cl- cotransporter, leading to reduced sodium reabsorption. As a result, sodium and water are retained in the lumen of the nephron for urinary excretion. The effects that follow include reduced plasma volume, reduced venous return, lower cardiac output, and ultimately decreased blood pressure. Interestingly, it is likely that thiazide-like diuretics such as indapamide have additional blood pressure lowering mechanisms that are unrelated to diuresis. This is exemplified by the observation that the antihypertensive effects of thiazides are sustained 4-6 weeks after initiation of therapy, despite recovering plasma and extracellular fluid volumes. Some studies have suggested that indapamide may decrease responsiveness to pressor agents while others have suggested it can decrease peripheral resistance. Although it is clear that diuresis contributes to the antihypertensive effects of indapamide, further studies are needed to investigate the medication’s ability to decrease peripheral vascular resistance and relax vascular smooth muscle.

Pharmacodynamics

Classified as a sulfonamide diuretic, indapamide is an effective antihypertensive agent and by extension, has shown efficacy in the prevention of target organ damage. Administration of indapamide produces water and electrolyte loss, with higher doses associated with increased diuresis. Severe and clinically significant electrolyte disturbances may occur with indapamide use - for example, hypokalemia resulting from renal potassium loss may lead to QTc prolongation. Further electrolyte imbalances may occur due to renal excretion of sodium, chloride, and magnesium. Other indapamide induced changes include increases in plasma renin and aldosterone, and reduced calcium excretion in the urine. In many studies investigating the effects of indapamide in both non-diabetic and diabetic hypertensive patients, glucose tolerance was not significantly altered. However, additional studies are necessary to assess the long term metabolic impacts of indapamide, since thiazide related impaired glucose tolerance can take several years to develop in non-diabetic patients.

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.